Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

v2.4.0.8
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (USD $)
3 Months Ended 6 Months Ended
Jun. 30, 2014
Jun. 30, 2013
Jun. 30, 2014
Jun. 30, 2013
Condensed Consolidated Statements Of Operations        
Revenues            
Operating expenses:        
Amortization & depreciation 194 194 388 388
General and administrative 156,285 229,850 294,911 463,491
Total operating expenses 156,479 230,044 295,299 463,879
Gain (loss) from operations (156,479) (230,044) (295,299) (463,879)
Other income (expense):        
Loss on fair value adjustment - derivatives 1,791 (293,684) (8,260) (389,297)
Gain on debt reversal          5,571
Interest expense (45,811) (25,657) (87,665) (66,057)
Interest expense - beneficial conversion feature (9,001) (56,389) (19,665) (133,492)
Total other income (expense) (53,021) (375,730) (115,590) (583,275)
Loss before provision for income taxes (209,500) (605,774) (410,889) (1,047,154)
Provision for income tax            
Net loss (209,500) (605,774) (410,889) (1,047,154)
Less: Net loss attributable to noncontrolling interest 1,173 2,280 2,367 5,185
Net loss attributable to TranBioTec, Inc. $ (208,327) $ (603,494) $ (408,522) $ (1,041,969)
Net loss per share        
(Basic and fully diluted) $ (0.01) $ (0.02) $ (0.01) $ (0.03)
Weighted average number of common shares outstanding 36,539,241 31,796,478 35,773,532 31,291,992